T1	studyType 86 126	A prospective randomized crossover trial
T2	studyType 155 206	prospective, controlled, randomized crossover trial
T4	drug 295 307	cyclosporine
T5	population 332 340	10 adult
T9	mode 721 725	oral
T11	drug 871 874	CyA
T12	pharmacokinetics 910 913	AUC
T15	drug 1227 1230	CyA
T16	pharmacokinetics 1339 1357	systemic clearance
T17	drug 1361 1364	CyA
T18	interaction 1511 1525	did not affect
T19	drug 1526 1529	CyA
T21	drug 43 55	cyclosporine
T22	meal 60 66	lipids
T23	mode 246 256	parenteral
T3	meal 268 290	with or without lipids
T24	mode 18 28	Parenteral
T6	meal 430 440	isocaloric
T20	meal 445 459	isonitrogenous
T7	mode 460 470	parenteral
T25	meal 492 538	without (regimen A) or with lipids (regimen B)
T26	parameter 654 667	Blood samples
T27	parameter 839 852	blood samples
T13	pharmacokinetics 916 936	trough concentration
T28	pharmacokinetics 941 959	systemic clearance
T14	interaction 1162 1202	no statistically significant differences
#1	AnnotatorNotes T14	pas d'interaction (no_effect_on_drug)
T8	interaction 1270 1317	no significant differences from baseline values
A1	valence T8 Négation
#2	AnnotatorNotes T8	no_effect
A2	valence T14 Négation
T29	interaction 1332 1338	higher
A3	valence T29 Augmentation
T31	drug 309 312	CyA
T32	pharmacokinetics 888 908	area under the curve
T33	pharmacokinetics 314 330	pharmacokinetics
T34	treatedDisease 391 418	bone marrow transplantation
T10	pharmacokinetics 1231 1257	pharmacokinetic parameters
T35	treatedDisease 698 713	transplantation
T36	dosage 1442 1452	0.8 g/Kg/d
T30	meal 1458 1510	50:50 mixture of medium and long chain triglycerides
A4	valence T18 Négation
R1	relation Arg1:T30 Arg2:T19	
#3	AnnotatorNotes R1	no effect on drug
